

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2020 November 14; 26(42): 6514-6705



**EDITORIAL**

- 6514 Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management  
*Chrysavgis L, Ztriva E, Protopapas A, Tziomalos K, Cholongitas E*

**REVIEW**

- 6529 Simultaneous colorectal and parenchymal-sparing liver resection for advanced colorectal carcinoma with synchronous liver metastases: Between conventional and mini-invasive approaches  
*De Raffele E, Mirarchi M, Cuicchi D, Lecce F, Casadei R, Ricci C, Selva S, Minni F*
- 6556 What could microRNA expression tell us more about colorectal serrated pathway carcinogenesis?  
*Peruhova M, Peshevska-Sekulovska M, Krastev B, Panayotova G, Georgieva V, Konakchieva R, Nikolaev G, Velikova TV*

**MINIREVIEWS**

- 6572 Modern surgical strategies for perianal Crohn's disease  
*Zabot GP, Cassol O, Saad-Hossne R, Bemelman W*
- 6582 Vascular anomalies associated with hepatic shunting  
*Schmalz MJ, Radhakrishnan K*

**ORIGINAL ARTICLE****Basic Study**

- 6599 Reactive oxygen species-induced activation of Yes-associated protein-1 through the c-Myc pathway is a therapeutic target in hepatocellular carcinoma  
*Cho Y, Park MJ, Kim K, Kim SW, Kim W, Oh S, Lee JH*
- 6614 Fedora-type magnetic compression anastomosis device for intestinal anastomosis  
*Chen H, Ma T, Wang Y, Zhu HY, Feng Z, Wu RQ, Lv Y, Dong DH*

**Retrospective Cohort Study**

- 6626 Attention deficit hyperactivity disorder and gastrointestinal morbidity in a large cohort of young adults  
*Kedem S, Yust-Katz S, Carter D, Levi Z, Kedem R, Dickstein A, Daher S, Katz LH*
- 6638 Nomograms and risk score models for predicting survival in rectal cancer patients with neoadjuvant therapy  
*Wei FZ, Mei SW, Chen JN, Wang ZJ, Shen HY, Li J, Zhao FQ, Liu Z, Liu Q*

**Observational Study**

- 6658** Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease

*Hernández-Conde M, Llop E, Fernández Carrillo C, Tormo B, Abad J, Rodríguez L, Perelló C, López Gomez M, Martínez-Porras JL, Fernández Puga N, Trapero-Marugan M, Fraga E, Ferre Aracil C, Calleja Panero JL*

**Prospective Study**

- 6669** Accuracy of carbon dioxide insufflation for endoscopic retrograde cholangiopancreatography using double-balloon endoscopy

*Niwa Y, Nakamura M, Kawashima H, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa E, Ishikawa T, Kakushima N, Furukawa K, Ohno E, Honda T, Ishigami M, Fujishiro M*

**SYSTEMATIC REVIEWS**

- 6679** Prognostic role of artificial intelligence among patients with hepatocellular cancer: A systematic review

*Lai Q, Spoletini G, Mennini G, Larghi Laureiro Z, Tsilimigras DI, Pawlik TM, Rossi M*

**CASE REPORT**

- 6689** Case series of three patients with hereditary diffuse gastric cancer in a single family: Three case reports and review of literature

*Hirakawa M, Takada K, Sato M, Fujita C, Hayasaka N, Nobuoka T, Sugita S, Ishikawa A, Mizukami M, Ohnuma H, Murase K, Miyanishi K, Kobune M, Takemasa I, Hasegawa T, Sakurai A, Kato J*

- 6698** Intussusception due to hematogenous metastasis of hepatocellular carcinoma to the small intestine: A case report

*Mashiko T, Masuoka Y, Nakano A, Tsuruya K, Hirose S, Hirabayashi K, Kagawa T, Nakagohri T*

**ABOUT COVER**

Editorial Board Member of *World Journal of Gastroenterology*, Dr. Misha Luyer is a Senior Consultant for upper gastrointestinal and pancreas surgery and Chair of the Department of Surgery. After finishing his surgical training in 2010, he started as a Fellow at the Catharina Hospital in Eindhoven (Netherlands), where he received specialized training in upper gastrointestinal, bariatric and pancreatic surgery. In 2012, he was appointed consultant at the Catharina Hospital. Since then, he has been involved in national training courses for minimally invasive upper gastrointestinal surgery and pancreatic surgery. He has authored more than 150 articles published in peer-reviewed scientific journals and book chapters in the fields of upper gastroenterology and pancreas. He currently serves on the Editorial Board of several peer-reviewed scientific journals. (L-Editor: Filipodia)

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastroenterology* (*WJG, World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. *WJG* mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

**INDEXING/ABSTRACTING**

The *WJG* is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2020 edition of Journal Citation Report® cites the 2019 impact factor (IF) for *WJG* as 3.665; IF without journal self cites: 3.534; 5-year IF: 4.048; Ranking: 35 among 88 journals in gastroenterology and hepatology; and Quartile category: Q2.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Ji-Hong Liu; Production Department Director: Yun-Xiaoqian Wu; Editorial Office Director: Ze-Mao Gong.

**NAME OF JOURNAL**

*World Journal of Gastroenterology*

**ISSN**

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

**LAUNCH DATE**

October 1, 1995

**FREQUENCY**

Weekly

**EDITORS-IN-CHIEF**

Andrzej S Tarnawski, Subrata Ghosh

**EDITORIAL BOARD MEMBERS**

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

**PUBLICATION DATE**

November 14, 2020

**COPYRIGHT**

© 2020 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

## Prognostic role of artificial intelligence among patients with hepatocellular cancer: A systematic review

Quirino Lai, Gabriele Spoletini, Gianluca Mennini, Zoe Larghi Laureiro, Diamantis I Tsilimigras, Timothy Michael Pawlik, Massimo Rossi

**ORCID number:** Quirino Lai 0000-0002-5403-6571; Gabriele Spoletini 0000-0002-6855-4515; Gianluca Mennini 0000-0002-6412-6863; Zoe Larghi Laureiro 0000-0003-4183-2017; Diamantis I Tsilimigras 0000-0002-3676-9263; Timothy Michael Pawlik 0000-0002-4828-8096; Massimo Rossi 0000-0001-5105-4656.

**Author contributions:** Lai Q designed the study; Rossi M gave administrative support; Lai Q and Larghi Laureiro Z collected the data; Lai Q, Spoletini G, Mennini G, Larghi Laureiro Z and Tsilimigras DI analyzed and interpreted the data; Lai Q, Spoletini G, and Pawlik TM wrote the manuscript; all the authors approved the final version of the manuscript.

**Conflict-of-interest statement:** The authors have no conflict of interest to declare.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised in accordance with this checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative

**Quirino Lai, Gianluca Mennini, Zoe Larghi Laureiro, Massimo Rossi,** Hepato-biliary and Organ Transplant Unit, Department of Surgery, Sapienza University of Rome, Rome 00161, Italy

**Gabriele Spoletini,** General Surgery and Liver Transplantation Unit, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome 00100, Italy

**Diamantis I Tsilimigras, Timothy Michael Pawlik,** Wexner Medical Center, The Ohio State University, Columbus, OH 43210, United States

**Corresponding author:** Quirino Lai, MD, PhD, Academic Fellow, Academic Research, Assistant Lecturer, Doctor, Senior Lecturer, Hepato-biliary and Organ Transplant Unit, Department of Surgery, Sapienza University of Rome, Roma, Rome 00161, Italy. [quirino.lai@uniroma1.it](mailto:quirino.lai@uniroma1.it)

### Abstract

#### BACKGROUND

Prediction of survival after the treatment of hepatocellular carcinoma (HCC) has been widely investigated, yet remains inadequate. The application of artificial intelligence (AI) is emerging as a valid adjunct to traditional statistics due to the ability to process vast amounts of data and find hidden interconnections between variables. AI and deep learning are increasingly employed in several topics of liver cancer research, including diagnosis, pathology, and prognosis.

#### AIM

To assess the role of AI in the prediction of survival following HCC treatment.

#### METHODS

A web-based literature search was performed according to the Preferred Reporting Items for Systemic Reviews and Meta-Analysis guidelines using the keywords "artificial intelligence", "deep learning" and "hepatocellular carcinoma" (and synonyms). The specific research question was formulated following the patient (patients with HCC), intervention (evaluation of HCC treatment using AI), comparison (evaluation without using AI), and outcome (patient death and/or tumor recurrence) structure. English language articles were retrieved, screened, and reviewed by the authors. The quality of the papers was assessed using the Risk of Bias In Non-randomized Studies of Interventions tool. Data were extracted and collected in a database.

#### RESULTS

Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Italy

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B  
Grade C (Good): 0  
Grade D (Fair): 0  
Grade E (Poor): 0

**Received:** August 29, 2020

**Peer-review started:** August 29, 2020

**First decision:** September 12, 2020

**Revised:** September 14, 2020

**Accepted:** October 1, 2020

**Article in press:** October 1, 2020

**Published online:** November 14, 2020

**P-Reviewer:** Lerut JP

**S-Editor:** Chen XF

**L-Editor:** A

**P-Editor:** Liu JH



Among the 598 articles screened, nine papers met the inclusion criteria, six of which had low-risk rates of bias. Eight articles were published in the last decade; all came from eastern countries. Patient sample size was extremely heterogenous ( $n = 11-22926$ ). AI methodologies employed included artificial neural networks (ANN) in six studies, as well as support vector machine, artificial plant optimization, and peritumoral radiomics in the remaining three studies. All the studies testing the role of ANN compared the performance of ANN with traditional statistics. Training cohorts were used to train the neural networks that were then applied to validation cohorts. In all cases, the AI models demonstrated superior predictive performance compared with traditional statistics with significantly improved areas under the curve.

## CONCLUSION

AI applied to survival prediction after HCC treatment provided enhanced accuracy compared with conventional linear systems of analysis. Improved transferability and reproducibility will facilitate the widespread use of AI methodologies.

**Key Words:** Deep learning; Artificial neuronal network; Recurrence; Liver transplantation; Resection; Hepatocellular cancer

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Prediction of survival after the treatment of hepatocellular carcinoma (HCC) has been widely investigated yet remains inadequate. The application of artificial intelligence (AI) is an emerging adjunct to traditional statistics due to its ability to process vast amounts of data and find hidden interconnections between variables. The current study aimed to assess the role of various methodologies of AI in the prediction of survival after treatment of HCC by performing a systematic review of the literature.

**Citation:** Lai Q, Spoletni G, Mennini G, Larghi Laureiro Z, Tsilimigras DI, Pawlik TM, Rossi M. Prognostic role of artificial intelligence among patients with hepatocellular cancer: A systematic review. *World J Gastroenterol* 2020; 26(42): 6679-6688

**URL:** <https://www.wjgnet.com/1007-9327/full/v26/i42/6679.htm>

**DOI:** <https://dx.doi.org/10.3748/wjg.v26.i42.6679>

## INTRODUCTION

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the third most common cause of cancer-related death worldwide. Surgery, in the form of liver transplantation and resection, is the mainstay of treatment as the only potentially curative treatment option. Ablation has emerged as an alternative treatment to resection for small tumors. In contrast, intra-arterial treatments and chemotherapy can offer disease control and be used as part of a multimodal therapeutic strategy<sup>[1]</sup>.

Many factors affect survival following the treatment of HCC. Among them, we can consider background liver condition, radiologic and histologic characteristics of the tumor, biologic markers, and comorbidities.

Traditionally, conventional linear models, such as the survival analysis and the Cox proportional hazard models, have been used to evaluate the prognosis of HCC<sup>[2-4]</sup>. Nevertheless, linear systems can have considerable limitations and often fail to capture the complexity of the interactions among clinicopathological characteristics<sup>[5]</sup>. With the intent to overcome such constraints, artificial intelligence (AI) has been employed with growing interest in healthcare research during the last decade, in particular applying deep learning (DL) techniques in artificial neural networks (ANN)<sup>[6]</sup>. ANN is a mathematical model that resembles the structure and function of a biological neural system using computer technology. It consists of a highly interconnected set of units, beginning with an input layer (the data to be analyzed), one or more hidden layers that process the data, and an output layer that provides the outcomes. The peculiarity

of ANN is that it can be trained by exposing the network to examples of input/output pairs, thus improving its reliability<sup>[7]</sup>. During DL, the model reassigns a different weight to the connections within each hidden layer. ANN can learn from errors by comparing any generated output with desired outputs. The error is backpropagated, and the existing weights between connections are modified accordingly. Once learning is complete, ANN can create connections and make predictions on datasets that have not been observed before.

AI has been used to build models to predict a variety of outcomes related to HCC, such as tumor diagnosis, pathology characteristics, response to treatment, and survival<sup>[7,8]</sup>. With the growing availability of big data from fields such as genomics, AI can unravel otherwise hidden connections between tumor elements because of the increasing computational power of modern technology<sup>[9]</sup>.

The objective of the current study was to systematically review the application of AI and DL in the prediction of survival among patients who were treated for HCC, as well as compare the performance of AI methods relative to linear prediction models.

---

## MATERIALS AND METHODS

---

### **Search sources and study design**

A systematic review of the published literature focused on the prognostic impact of AI in the management of HCC was undertaken. The search strategy was performed following the Preferred Reporting Items for Systemic Reviews and Meta-Analysis (PRISMA) guidelines<sup>[10]</sup>.

The specific research question formulated in the present study includes the following PICO components: (1) Patient: Patient with a confirmed HCC; (2) Intervention: Evaluation of HCC treatment using AI; (3) Comparison: Evaluation of HCC treatment without using AI; and (4) Outcome: Patient death and/or tumor recurrence. A search of the PubMed and Cochrane Central Register of Controlled Trials Databases was conducted using the following terms: (Artificial intelligence OR deep learning) AND (HCC OR hepatocellular carcinoma OR hepatocellular cancer). The search period was from "1985/01/01" to "2020/02/29".

The systematic qualitative review included only English studies that included human patients. Published reports were excluded based on several criteria: (1) Data on animal models; (2) Lacked enough clinical details; and (3) Had non-primary source data (*e.g.*, review articles, non-clinical studies, letters to the editor, expert opinions, and conference summaries). In the case of studies originating from the same center, possible overlapping of clinical cases was examined, and the most informative study was considered eligible.

### **Data extraction and definitions**

Following a full-text review of the eligible studies, two independent authors (Lai Q and Larghi Laureiro Z) performed the data extraction and crosschecked all outcomes. During the selection of articles and extraction of the data, potential discrepancies were resolved following a consensus with a third reviewer (Mennini G). Collected data included the first author of the publication, year of publication, country, number of reported cases, research question/purpose, the method used, and key findings.

### **Quality assessment**

Selected studies were systematically reviewed with the intent to identify potential sources of bias. The quality of the papers was assessed using the Risk of Bias In Non-randomized Studies of Interventions tool<sup>[11]</sup>.

---

## RESULTS

---

### **Search results and study characteristics**

The PRISMA flow diagram schematically depicts the article selection process (Figure 1). Among the 598 articles screened, a total of 127 studies reported on the use of AI in HCC. Among these articles, only 9 (7.1%) studies referred to the use of AI in the prediction of survival among patients with HCC and were included in this review<sup>[12-20]</sup>. Other studies using AI in HCC were excluded; specifically, these studies reported on the use of AI for the diagnosis of the tumor ( $n = 76$ , 59.8%), identification of specific genes or pathways ( $n = 17$ , 13.4%), prediction of tumor response after




Figure 1 Preferred Reporting Items for Systemic Reviews and Meta-Analysis flowchart of the literature search and study selection.

therapy ( $n = 16$ , 12.6%), and the prediction of pathological aspects ( $n = 9$ , 7.1%) (Figure 2). All studies included in the analytic cohort were published in the last decade except for one that was published in 1995<sup>[12]</sup>. All articles were from Asia; five studies were based on a population from Taiwan<sup>[13-17]</sup>, two from China<sup>[18,20]</sup>, one from Japan<sup>[12]</sup>, and one from India<sup>[19]</sup>.

### Qualitative assessment of the included studies

Results from the qualitative assessment of the included studies are depicted in Figure 3. Six studies had a low risk of bias, while two studies were at high risk for bias, mainly due to the presence of potential confounders. In one study, due to the absence of clear data explaining the characteristics of the comparison groups, the risk of bias was unclear.

### Review of the eligible studies

Data extracted from the nine eligible articles are reported in detail in Table 1. The largest studies were based on the same population of patients coming from the Taiwan Bureau of National Health Insurance. All patients had a diagnosis of a malignant neoplasm of the liver and underwent a hepatectomy between 1998-2009 ( $n = 22926$ )<sup>[14,15]</sup>. In all other studies, the sample size was smaller than 1000 cases, and in two cases, the sample size was smaller than 100<sup>[12,17]</sup>.

The use of ANN in populations of patients who underwent surgery was reported in six articles<sup>[12-16,18]</sup>. The outcomes investigated included in-hospital postoperative mortality<sup>[14]</sup>, long-term overall survival<sup>[12,15,16,18]</sup>, and disease-free survival after hepatic resection<sup>[13]</sup>. Several other studies used different AI systems rather than ANN. Specifically, a support vector machine was used for the development of predictive models relative to the recurrence of HCC following radiofrequency ablation<sup>[17]</sup>. Besides, an Artificial Plant Optimization algorithm was used to assess the effectiveness and efficiency to predict HCC recurrence<sup>[19]</sup>. Peritumoral radiomics was used to predict early recurrence after HCC curative-intent resection or ablation<sup>[20]</sup>.

A cohort was used in the majority of studies to train the AI network<sup>[12-16,18,20]</sup>; in one study, a double five-fold cross-validation loop method was adopted<sup>[17]</sup>. In all studies, AI demonstrated superior predictive performance compared with other traditional models. In several studies, the ANN outperformed logistic regression or Cox regression models<sup>[13-16,18]</sup>. In all cases, the prediction accuracy of the AI models expressed as the areas under the curve was significantly improved compared with traditional statistical techniques<sup>[13-16,18]</sup>.


**Table 1** Articles focused on the role of artificial intelligence in the prediction of survival

Ref.	Country/region	n	Research question/purpose	Method used	Key findings
Hamamoto <i>et al</i> <sup>[12]</sup> , 1995	Japan	11	ANN for the prediction of survival after HCC resection.	ANN was trained with the data of 54 resected patients and then prospectively used.	The outcomes in the prospective cohort were successfully predicted in all the cases (10 successful, 1 died).
Ho <i>et al</i> <sup>[13]</sup> , 2012	Taiwan	482	To validate the use of ANN model for predicting 1-, 3-, and 5-yr disease-free survival after hepatic resection, and to compare it with LR and decision tree model.	Training set: 80% of the cases; validation set: Remaining 20% of the cases.	The ANN model outperformed the other models in terms of prediction accuracy (AUC for 5-yr disease-free survival: 0.864 <i>vs</i> 0.627-0.736).
Shi <i>et al</i> <sup>[14]</sup> , 2012	Taiwan	22926	ANN model for predicting in-hospital mortality in HCC surgery patients and to compare it with LR models.	This study analyzed administrative claims data obtained from the Taiwan Bureau of National Health Insurance.	Compared to the LR models, the ANN models had a better accuracy rate in 97.28% of cases, and a better ROC curve in 84.67% of cases.
Shi <i>et al</i> <sup>[15]</sup> , 2012	Taiwan	22926	To validate the ANN models for predicting 5-yr mortality in HCC resected patients, and to compare them with LR models.	This study analyzed administrative claims data obtained from the Taiwan Bureau of National Health Insurance.	Compared to the LR models, the ANN models had a better accuracy rate in 96.57% of cases, and a better receiver operating characteristic curves in 88.51% of cases.
Chiu <i>et al</i> <sup>[16]</sup> , 2013	Taiwan	434	To compare significant predictors of mortality for HCC resected patients between ANN and LR models, and to evaluate the predictive accuracy of ANN and LR in different survival year estimation models.	Training set: 80% of the cases; validation set: Remaining 20% of the cases.	The results indicated that ANN had double to triple numbers of significant predictors at 1-, 3-, and 5-yr survival models as compared with LR models. Scores of accuracy, sensitivity, specificity, and AUC using ANN were superior to those of LR.
Qiao <i>et al</i> <sup>[17]</sup> , 2014	China	543; 182; 104	ANN for the prediction of survival in early HCC cases following partial hepatectomy.	Training set: 75% of the cases; internal validation set: Remaining 25% of the cases; external validation set.	In the training cohort, the AUC of the ANN was larger than that of the Cox model (0.855 <i>vs</i> 0.826, <i>P</i> = 0.0115). These findings were confirmed with the internal and external validation cohorts.
Liang <i>et al</i> <sup>[18]</sup> , 2014	Taiwan	83	Use of support vector machine for the development of recurrence predictive models for HCC patients receiving RFA treatment.	Five feature selection methods including genetic algorithm, simulated annealing algorithm, random forests and hybrid methods were utilized.	The developed support vector machine-based predictive models using hybrid methods had averages of the sensitivity, specificity, and AUC as 67%, 86%, and 0.69.
R <i>et al</i> <sup>[19]</sup> , 2019	India	152	To use artificial plant optimization algorithm to select optimal features and parameters of classifiers to improve the effectiveness and efficiency of prediction of HCC recurrence.	Different methods tested.	The sampling based multiple measurement artificial plant optimized random forest classifier with statistical measure showed the best results (balanced accuracy: 0.955).
Shan <i>et al</i> <sup>[20]</sup> , 2019	China	156	Peritumoral radiomics for the prediction of early recurrence after HCC curative resection or ablation.	Training cohort ( <i>n</i> = 109) and validation cohort ( <i>n</i> = 47). Using CT images, two regions of interest were delineated around the lesion for feature extraction o tumoral radiomics and peritumoral radiomics.	In the validation cohort, the ROC curves, calibration curves and decision curves indicated that the CT-based peritumoral radiomics model had better calibration efficiency and provided greater clinical benefits.


ANN: Artificial neural network; HCC: Hepatocellular carcinoma; AUC: Area under the curve; LR: Logistic regression; RFA: Radiofrequency ablation; CT: Computed tomography; ROC: Receiver operating characteristic.

## DISCUSSION

The use of AI in healthcare began in the early 1970s and has gained increased acceptance over the last decades. In particular, the development of AI in medical research and its clinical applications have gained popularity, in part because of the widespread use of AI in almost all fields of human life<sup>[21]</sup>. The current literature search revealed that many AI studies focused on diagnosis, and the application of AI to distinguish the radiological features of HCC. The identification and diagnostic



**Figure 2** Different articles exploring the impact of artificial intelligence as diagnostic or prognostic tool in the setting of hepatocellular carcinoma management. AI: Artificial intelligence; HCC: Hepatocellular carcinoma; LRT: Locoregional therapy.



**Figure 3** Results of the Risk of Bias In Non-randomized Studies of Interventions tool for the extracted articles.

discrimination of benign *vs* malignant liver masses has been the objective of a previous systematic review that noted AI could differentiate liver cancer and, in particular, HCC from other lesions better compared with other methods such as Bayesian models and expert radiologists image inspection<sup>[6]</sup>. The present systematic review is important because it is the first to summarize the ability of AI systems to predict patient survival following treatment of HCC. Our results revealed that different types of AI methods have been employed in the existing studies with heterogeneous patient sample sizes. The majority of the included studies ( $n = 6/9$ ) utilized ANN for the analysis of predictors of post-treatment survival, which is in line with the results of other systematic reviews on the prediction of outcomes<sup>[22,23]</sup>. Considering the need for more

accurate prediction, investigators have compared AI techniques with traditional linear models to optimize treatment decision-making. Although several prediction models have utilized both pre- and postoperative variables, these models have not proved useful in clinical decision-making since they require information that can only be available after resection or other treatment. In contrast, models with only preoperative variables can help guide treatment strategies in the preoperative setting<sup>[24,25]</sup>.

Importantly, our systematic review revealed that the prediction of survival using AI methodology was highly accurate and remained robust in studies with limited sample sizes, although current knowledge in prediction modeling using AI has noted that AI performs better when applied to larger sample sizes<sup>[26]</sup>. Although the reason for the consistent high predictive accuracy of AI models is multifactorial, the complexity of AI models (*e.g.*, a higher number of events per variable) further reinforces the superiority of their performance, which might explain the outstanding results even when used in smaller size studies<sup>[27]</sup>.

Reproducibility and applicability of AI models in clinical practice and across different centers might be questioned due to the difficulties in acquiring and utilizing a dedicated software to process the data. In addition, as ANN learns from examples, one may argue that ANN needs to be trained before it can be applied to varying datasets that are different from the one it was initially built on. Nevertheless, what emerged from this systematic review was that AI could be an outstanding adjunct to conventional linear systems of analysis to predict post-treatment survival. Cucchetti *et al*<sup>[7]</sup> made their ANN available online so that other centers can test and possibly enrich their model aiming to predict HCC tumor grade and micro-vascular invasion preoperatively. Besides, when applied to other aspects of HCC, AI is particularly useful for exploring interconnections of big data such as in genomics. ANN combined with genotyping for microsatellite mutations/deletions was able to predict HCC recurrence after liver transplantation with an 85% accuracy in the center where the model was developed, and with 89.5% accuracy when examined in data from another center<sup>[28]</sup>. AI applied to radiomics is increasingly investigated: Machine learning has been used to provide a quantitative interpretation of computed tomography scans to reclassify indeterminate nodules and potentially avoid biopsy and improve patients safety<sup>[29]</sup>. Similarly, neural network algorithms have been built with the intent to objectively and reproducibly provide liver imaging reporting and data system categories concordant with the expert radiologists classification<sup>[30]</sup>.

One of the downsides associated with the application of ANN in clinical practice might be the disproportionate number of input factors per patient (too many, *e.g.*, thousands of proteins for gene expression) relative to the number of patients (too little). The risk of overfitting the dataset can be mitigated by strictly filtering out potentially irrelevant variables<sup>[31]</sup>. In particular, selecting the variables to use as input factors in ANN using traditional statistics has been employed as a strategy to improve efficiency and reduce redundancy of the AI model, as confirmed by all of the studies using ANNs included in this systematic review. When analyzing cancer patient data (*i.e.*, too many dimensions for a relatively small number of samples), combining DL with other techniques of machine learning have been used to identify prognostic gene signatures and differentiate between better and worse prognosis in patients with various types of tumors including HCC<sup>[32]</sup>.

---

## CONCLUSION

---

Artificial intelligence can provide an enhanced prediction of survival following treatment of HCC compared with conventional linear models. The use of AI can be particularly helpful to process large amounts of data, as well as help identify patterns and associations that are not evident with traditional techniques given the complexity of the biological systems. AI has a promising role in health-care research and its application to HCC. While an increasing amount of data becomes available per patient, it is important to identify to what extent AI can help guide clinical decision-making and optimize the prediction of long-term outcomes based on the unique characteristics of each patient.

## ARTICLE HIGHLIGHTS

### Research background

Prediction of survival after the treatment of hepatocellular carcinoma (HCC) has been widely investigated, yet remains inadequate. The application of artificial intelligence (AI) is emerging as a valid adjunct to traditional statistics due to the ability to process vast amounts of data and find hidden interconnections between variables. AI and deep learning are increasingly employed in several topics of liver cancer research, including diagnosis, pathology, and prognosis.

### Research motivation

AI applied to survival prediction after HCC treatment should provide enhanced accuracy compared with conventional linear systems of analysis.

### Research objectives

Improved transferability and reproducibility will facilitate the widespread use of AI methodologies.

### Research methods

A web-based literature search was performed according to the Preferred Reporting Items for Systemic Reviews and Meta-Analysis guidelines using the keywords “artificial intelligence”, “deep learning” and “hepatocellular carcinoma” (and synonyms).

### Research results

Among the 598 articles screened, nine papers met the inclusion criteria, six of which had low-risk rates of bias. Eight articles were published in the last decade; all came from eastern countries. Patient sample size was extremely heterogeneous ( $n = 11-22926$ ). AI methodologies employed included artificial neural networks (ANN) in six studies, as well as support vector machine, artificial plant optimization, and peritumoral radiomics in the remaining three studies. All the studies testing the role of ANN compared the performance of ANN with traditional statistics. Training cohorts were used to train the neural networks that were then applied to validation cohorts. In all cases, the AI models demonstrated superior predictive performance compared with traditional statistics with significantly improved areas under the curve.

### Research conclusions

AI applied to survival prediction after HCC treatment provided enhanced accuracy compared with conventional linear systems of analysis.

### Research perspectives

Improved transferability and reproducibility will facilitate the widespread use of AI methodologies.

## REFERENCES

- 1 Vitale A, Trevisani F, Farinati F, Cillo U. Treatment of hepatocellular carcinoma in the Precision Medicine era: from treatment stage migration to therapeutic hierarchy. *Hepatology* 2020; Online ahead of print [PMID: 32064645 DOI: 10.1002/hep.31187]
- 2 Vitale A, Lai Q, Farinati F, Bucci L, Giannini EG, Napoli L, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F, Pawlik TM; Italian Liver Cancer (ITA. LI.CA) group. Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. *J Gastrointest Surg* 2018; 22: 859-871 [PMID: 29352441 DOI: 10.1007/s11605-018-3688-y]
- 3 Lai Q, Vitale A, Halazun K, Iesari S, Viveiros A, Bhangu P, Mennini G, Wong T, Uemoto S, Lin CC, Mittler J, Ikegami T, Zhe Y, Zheng SS, Soejima Y, Hoppe-Lotichius M, Chen CL, Kaido T, Lo CM, Rossi M, Soin AS, Finkenstedt A, Emond JC, Cillo U, Lerut J. Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort. *Cancers (Basel)* 2020; 12: 452 [PMID: 32075133 DOI: 10.3390/cancers12020452]
- 4 Lai Q, Nicolini D, Inostroza Nunez M, Iesari S, Goffette P, Agostini A, Giovagnoni A, Vivarelli M, Lerut J. A Novel Prognostic Index in Patients With Hepatocellular Cancer Waiting for Liver Transplantation: Time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) Score. *Ann Surg* 2016; 264: 787-796 [PMID: 27429025 DOI: 10.1097/SLA.0000000000001881]

- 5 **Huang S**, Yang J, Fong S, Zhao Q. Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challenges. *Cancer Lett* 2020; **471**: 61-71 [PMID: 31830558 DOI: 10.1016/j.canlet.2019.12.007]
- 6 **Cleophas TJ**, Cleophas TF. Artificial intelligence for diagnostic purposes: principles, procedures and limitations. *Clin Chem Lab Med* 2010; **48**: 159-165 [PMID: 20001439 DOI: 10.1515/CCLM.2010.045]
- 7 **Cucchetti A**, Piscaglia F, Grigioni AD, Ravaioli M, Cescon M, Zanello M, Grazi GL, Golfieri R, Grigioni WF, Pinna AD. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. *J Hepatol* 2010; **52**: 880-888 [PMID: 20409605 DOI: 10.1016/j.jhep.2009.12.037]
- 8 **Azer SA**. Deep learning with convolutional neural networks for identification of liver masses and hepatocellular carcinoma: A systematic review. *World J Gastrointest Oncol* 2019; **11**: 1218-1230 [PMID: 31908726 DOI: 10.4251/wjgo.v11.i12.1218]
- 9 **Chen B**, Garmire L, Calvisi DF, Chua MS, Kelley RK, Chen X. Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol* 2020; **17**: 238-251 [PMID: 31900465 DOI: 10.1038/s41575-019-0240-9]
- 10 **Hutton B**, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015; **162**: 777-784 [PMID: 26030634 DOI: 10.7326/M14-2385]
- 11 **Sterne JA**, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016; **355**: i4919 [PMID: 27733354 DOI: 10.1136/bmj.i4919]
- 12 **Hamamoto I**, Okada S, Hashimoto T, Wakabayashi H, Maeba T, Maeta H. Prediction of the early prognosis of the hepatectomized patient with hepatocellular carcinoma with a neural network. *Comput Biol Med* 1995; **25**: 49-59 [PMID: 7600761 DOI: 10.1016/0010-4825(95)98885-h]
- 13 **Ho WH**, Lee KT, Chen HY, Ho TW, Chiu HC. Disease-free survival after hepatic resection in hepatocellular carcinoma patients: a prediction approach using artificial neural network. *PLoS One* 2012; **7**: e29179 [PMID: 22235270 DOI: 10.1371/journal.pone.0029179]
- 14 **Shi HY**, Lee KT, Lee HH, Ho WH, Sun DP, Wang JJ, Chiu CC. Comparison of artificial neural network and logistic regression models for predicting in-hospital mortality after primary liver cancer surgery. *PLoS One* 2012; **7**: e35781 [PMID: 22563399 DOI: 10.1371/journal.pone.0035781]
- 15 **Shi HY**, Lee KT, Wang JJ, Sun DP, Lee HH, Chiu CC. Artificial neural network model for predicting 5-year mortality after surgery for hepatocellular carcinoma: a nationwide study. *J Gastrointest Surg* 2012; **16**: 2126-2131 [PMID: 22878787 DOI: 10.1007/s11605-012-1986-3]
- 16 **Chiu HC**, Ho TW, Lee KT, Chen HY, Ho WH. Mortality predicted accuracy for hepatocellular carcinoma patients with hepatic resection using artificial neural network. *ScientificWorldJournal* 2013; **2013**: 201976 [PMID: 23737707 DOI: 10.1155/2013/201976]
- 17 **Qiao G**, Li J, Huang A, Yan Z, Lau WY, Shen F. Artificial neural networking model for the prediction of post-hepatectomy survival of patients with early hepatocellular carcinoma. *J Gastroenterol Hepatol* 2014; **29**: 2014-2020 [PMID: 24989634 DOI: 10.1111/jgh.12672]
- 18 **Liang JD**, Ping XO, Tseng YJ, Huang GT, Lai F, Yang PM. Recurrence predictive models for patients with hepatocellular carcinoma after radiofrequency ablation using support vector machines with feature selection methods. *Comput Methods Programs Biomed* 2014; **117**: 425-434 [PMID: 25278224 DOI: 10.1016/j.cmpb.2014.09.001]
- 19 **R D**, P R. An Optimized HCC Recurrence Prediction Using APO Algorithm Multiple Time Series Clinical Liver Cancer Dataset. *J Med Syst* 2019; **43**: 193 [PMID: 31115780 DOI: 10.1007/s10916-019-1265-x]
- 20 **Shan QY**, Hu HT, Feng ST, Peng ZP, Chen SL, Zhou Q, Li X, Xie XY, Lu MD, Wang W, Kuang M. CT-based peritumoral radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation. *Cancer Imaging* 2019; **19**: 11 [PMID: 30813956 DOI: 10.1186/s40644-019-0197-5]
- 21 **Yasnitsky LN**. Artificial Intelligence and Medicine: History, Current State and Forecasts for the Future. *Curr Hypertens Rev* 2020 [PMID: 32664841 DOI: 10.2174/1573402116666200714150953]
- 22 **Senanayake S**, White N, Graves N, Healy H, Baboolal K, Kularatna S. Machine learning in predicting graft failure following kidney transplantation: A systematic review of published predictive models. *Int J Med Inform* 2019; **130**: 103957 [PMID: 31472443 DOI: 10.1016/j.ijmedinf.2019.103957]
- 23 **Abbod MF**, Catto JW, Linkens DA, Hamdy FC. Application of artificial intelligence to the management of urological cancer. *J Urol* 2007; **178**: 1150-1156 [PMID: 17698099 DOI: 10.1016/j.juro.2007.05.122]
- 24 **Tsilimigras DI**, Mehta R, Moris D, Sahara K, Bagante F, Paredes AZ, Farooq A, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultides GA, Popescu I, Grigorie R, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Utilizing Machine Learning for Pre- and Postoperative Assessment of Patients Undergoing Resection for BCLC-0, A and B Hepatocellular Carcinoma: Implications for Resection Beyond the BCLC Guidelines. *Ann Surg Oncol* 2020; **27**: 866-874 [PMID: 31696396 DOI: 10.1245/s10434-019-08025-z]
- 25 **Tsilimigras DI**, Mehta R, Moris D, Sahara K, Bagante F, Paredes AZ, Moro A, Guglielmi A, Aldrighetti L, Weiss M, Bauer TW, Alexandrescu S, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Soubrane O, Koerkamp BG, Endo I, Pawlik TM. A Machine-Based Approach to Preoperatively Identify Patients with the Most and Least Benefit Associated with Resection for Intrahepatic Cholangiocarcinoma: An International Multi-institutional Analysis of 1146 Patients. *Ann Surg Oncol* 2020; **27**: 1110-1119 [PMID: 31728792 DOI: 10.1245/s10434-019-08067-3]
- 26 **van der Ploeg T**, Austin PC, Steyerberg EW. Modern modelling techniques are data hungry: a simulation

- study for predicting dichotomous endpoints. *BMC Med Res Methodol* 2014; **14**: 137 [PMID: 25532820 DOI: 10.1186/1471-2288-14-137]
- 27 **Gaughlitz G.** Artificial vs. human intelligence in analytics : Do computers outperform analytical chemists? *Anal Bioanal Chem* 2019; **411**: 5631-5632 [PMID: 31240356 DOI: 10.1007/s00216-019-01972-2]
- 28 **Rodriguez-Luna H,** Vargas HE, Byrne T, Rakela J. Artificial neural network and tissue genotyping of hepatocellular carcinoma in liver-transplant recipients: prediction of recurrence. *Transplantation* 2005; **79**: 1737-1740 [PMID: 15973178 DOI: 10.1097/01.tp.0000161794.32007.d1]
- 29 **Mokrane FZ,** Lu L, Vavasour A, Otal P, Peron JM, Luk L, Yang H, Ammari S, Saenger Y, Rousseau H, Zhao B, Schwartz LH, Derce L. Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules. *Eur Radiol* 2020; **30**: 558-570 [PMID: 31444598 DOI: 10.1007/s00330-019-06347-w]
- 30 **Yamashita R,** Mittendorf A, Zhu Z, Fowler KJ, Santillan CS, Sirlin CB, Bashir MR, Do RKG. Deep convolutional neural network applied to the liver imaging reporting and data system (LI-RADS) version 2014 category classification: a pilot study. *Abdom Radiol* **45**: 24-35 [PMID: 31696269 DOI: 10.1007/s00261-019-02306-7]
- 31 **Bartosch-Härlid A,** Andersson B, Aho U, Nilsson J, Andersson R. Artificial neural networks in pancreatic disease. *Br J Surg* 2008; **95**: 817-826 [PMID: 18551536 DOI: 10.1002/bjs.6239]
- 32 **Choi J,** Oh I, Seo S, Ahn J. G2Vec: Distributed gene representations for identification of cancer prognostic genes. *Sci Rep* 2018; **8**: 13729 [PMID: 30213980 DOI: 10.1038/s41598-018-32180-0]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

